PARP1 and neoplasm: Accordingly, early clinical trials are underway in which either one of the alkylating agents temozolomide, carboplatin, mitomycin or other DNA-damaging agents are added in combination with a PARP-1 inhibitor to patients with mutant BRCA1/BRCA2 tumours (see details in Helleday et al, 2008 ; Lord and Ashworth, 2008).